Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial

Journal of Clinical Oncology

Volumn 34, Issue 27, 2016, Pages 3300-3307

  Deng, Yanhong ^a   Chi, Pan ^g   Lan, Ping ^a   Wang, Lei ^a   Chen, Weiqing ^a   Cui, Long ^h   Chen, Daoda ^j   Cao, Jie ^b   Wei, Hongbo ^a   Peng, Xiang ^k   Huang, Zonghai ^c   Cai, Guanfu ^d   Zhao, Ren ⁱ   Huang, Zhongcheng ^l   Xu, Lin ^m   Zhou, Hongfeng ^e   Wei, Yisheng ^f   Zhang, Hao ⁿ   Zheng, Jian ^a   Huang, Yan ^a   Zhou, Zhiyang ^a   Cai, Yue ^a   Kang, Liang ^a   Huang, Meijin ^a   Peng, Junsheng ^a   Ren, Donglin ^a   Wang, Jianping ^a   more..

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^f GUANGZHOU MEDICAL UNIVERSITY   (China)

^g FUJIAN MEDICAL UNIVERSITY   (China)

^h XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

ⁱ SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^j UNION HOSPITAL   (China)

^k THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^l HUNAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^m XIAMEN UNIVERSITY   (China)

ⁿ Dongguan Kanghua Hospital   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINESE; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; INTESTINE INFECTION; INTESTINE PERFORATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROCTITIS; RADIATION DERMATITIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; TOTAL MESORECTAL EXCISION; TREATMENT DURATION; ADJUVANT CHEMORADIOTHERAPY; CLINICAL TRIAL; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; RECTAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS;

EID: 84989929313     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.6198     Document Type: Article

References (25)

1. Benson AB III, Venook AP, Bekaii-Saab T, et al: Rectal cancer, version 2.2015. J Natl Compr Canc Netw 13:719-728, quiz 728, 2015
2. Glimelius B, Tiret E, Cervantes A, et al: Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi81-vi88, 2013 (suppl 6)
3. Khrizman P, Niland JC, ter Veer A, et al: Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: A National Comprehensive Cancer Network analysis. J Clin Oncol 31:30-38, 2013
4. van Gijn W, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575-582, 2011
5. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
6. Gérard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644, 2010
7. Aschele C, Cionini L, Lonardi S, et al: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773-2780, 2011
8. O'Connell MJ, Colangelo LH, Beart RW, et al: Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: Surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32:1927-1934, 2014
9. Rödel C, Graeven U, Fietkau R, et al: Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979-989, 2015
10. Rödel C, Liersch T, Becker H, et al: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679-687, 2012
11. Schmoll H-J, Haustermans K, Price T, et al: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. Proc Am Soc Clin Oncol 32:3501a, 2014
12. Peeters KC, van de Velde CJ, Leer JW, et al: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients - A Dutch Colorectal Cancer Group study. J Clin Oncol 23:6199-6206, 2005
13. Lange MM, den Dulk M, Bossema ER, et al: Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg 94:1278-1284, 2007
14. Bruheim K, Guren MG, Skovlund E, et al: Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76:1005-1011, 2010
15. Havenga K, Enker WE, Norstein J, et al: Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: An international analysis of 1411 patients. Eur J Surg Oncol 25:368-374, 1999
16. Hasegawa J, Nishimura J, Mizushima T, et al: Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol 73:1079-1087, 2014
17. Ishii Y, Hasegawa H, Endo T, et al: Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol 36:1061-1065, 2010
18. Schrag D, Weiser MR, Goodman KA, et al: Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial. J Clin Oncol 32:513-518, 2014
19. Uehara K, Hiramatsu K, Maeda A, et al: Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol 43:964-971, 2013
20. Chow SC, Liu JP. Randomization and blinding, in Design and Analysis of Clinical Trials (ed 2). Hoboken, NJ, Wiley, 2004, pp 120-166
21. Ryan R, Gibbons D, Hyland JM, et al: Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47:141-146, 2005
22. Ferrari L, Fichera A: Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. Gastroenterol Rep (Oxf) 3:277-288, 2015
23. Maas M, Nelemans PJ, Valentini V, et al: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 11:835-844, 2010
24. Garcia-Aguilar J, Chow OS, Smith DD, et al: Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16:957-966, 2015
25. Ueki T, Manabe T, Inoue S, et al: A feasibility study of neoadjuvant XELOX without radiotherapy for locally advanced lower rectal cancer. Anticancer Res 36:741-747, 2016